Business · 04/08/2009Updated: 10/17/2026 · 1 min read
FDA Determines Regulatory Review Period for RECOTHROM Patent Extension
Summary
The Food and Drug Administration (FDA) has officially confirmed the regulatory review period for RECOTHROM, a human biological product, in accordance with federal regulations, following the submission of patent extension applications to the Director of Patents and Trademarks at the Department of Commerce.
Original source language: Federal Register — Food and Drug AdministrationOpen original release →